316 related articles for article (PubMed ID: 27105345)
1. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.
Pinheiro C; Miranda-Gonçalves V; Longatto-Filho A; Vicente AL; Berardinelli GN; Scapulatempo-Neto C; Costa RF; Viana CR; Reis RM; Baltazar F; Vazquez VL
Cell Cycle; 2016 Jun; 15(11):1462-70. PubMed ID: 27105345
[TBL] [Abstract][Full Text] [Related]
2. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
Pinheiro C; Sousa B; Albergaria A; Paredes J; Dufloth R; Vieira D; Schmitt F; Baltazar F
Histol Histopathol; 2011 Oct; 26(10):1279-86. PubMed ID: 21870331
[TBL] [Abstract][Full Text] [Related]
3. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation.
Sáenz-de-Santa-María I; Bernardo-Castiñeira C; Secades P; Bernaldo-de-Quirós S; Rodrigo JP; Astudillo A; Chiara MD
Oncotarget; 2017 Feb; 8(8):13730-13746. PubMed ID: 28099149
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
6. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis.
Martins SF; Amorim R; Viana-Pereira M; Pinheiro C; Costa RF; Silva P; Couto C; Alves S; Fernandes S; Vilaça S; Falcão J; Marques H; Pardal F; Rodrigues M; Preto A; Reis RM; Longatto-Filho A; Baltazar F
BMC Cancer; 2016 Jul; 16():535. PubMed ID: 27460659
[TBL] [Abstract][Full Text] [Related]
7. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
8.
Chou CH; Chiang CF; Yang CC; Liu YC; Chang SR; Chang KW; Lin SC
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769160
[TBL] [Abstract][Full Text] [Related]
9. Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Cao YW; Liu Y; Dong Z; Guo L; Kang EH; Wang YH; Zhang W; Niu HT
Urol Oncol; 2018 Jun; 36(6):311.e15-311.e25. PubMed ID: 29657088
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells.
Diehl K; Dinges LA; Helm O; Ammar N; Plundrich D; Arlt A; Röcken C; Sebens S; Schäfer H
Oncogene; 2018 Jan; 37(1):39-51. PubMed ID: 28846107
[TBL] [Abstract][Full Text] [Related]
11. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors.
Pinheiro C; Granja S; Longatto-Filho A; Faria AM; Fragoso MC; Lovisolo SM; Lerário AM; Almeida MQ; Baltazar F; Zerbini MC
Oncotarget; 2015 Dec; 6(42):44403-21. PubMed ID: 26587828
[TBL] [Abstract][Full Text] [Related]
12. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
13. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
15. Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.
Kong SC; Nøhr-Nielsen A; Zeeberg K; Reshkin SJ; Hoffmann EK; Novak I; Pedersen SF
Pancreas; 2016 Aug; 45(7):1036-47. PubMed ID: 26765963
[TBL] [Abstract][Full Text] [Related]
16. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression.
Sanità P; Capulli M; Teti A; Galatioto GP; Vicentini C; Chiarugi P; Bologna M; Angelucci A
BMC Cancer; 2014 Mar; 14():154. PubMed ID: 24597899
[TBL] [Abstract][Full Text] [Related]
17. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
18. Characterization of glycolysis-related gene expression in malignant melanoma.
Koch A; Ebert EV; Seitz T; Dietrich P; Berneburg M; Bosserhoff A; Hellerbrand C
Pathol Res Pract; 2020 Jan; 216(1):152752. PubMed ID: 31791701
[TBL] [Abstract][Full Text] [Related]
19. Benign nodal nevi frequently harbor the activating V600E BRAF mutation.
Taube JM; Begum S; Shi C; Eshleman JR; Westra WH
Am J Surg Pathol; 2009 Apr; 33(4):568-71. PubMed ID: 19033861
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
